PIM3 and hepatoblastoma: Since PIM3 expression was increased in the cisplatin-resistant cells, we sought to determine whether combining the pan-PIM inhibitor, AZD1208, to cisplatin would more effectively decrease proliferation of cisplatin-resistant hepatoblastoma cells.